TY - JOUR
T1 - Evaluation of triazole-chelated lanthanides as chemically stabile bioimaging agents
AU - Indapurkar, Amruta
AU - Henriksen, Brian
AU - Tolman, Justin
AU - Fletcher, James
N1 - Funding Information:
The authors would like to acknowledge the Creighton University Integrated BIomedical Imaging Facility CUIBIF for assistance with Figure 5 . This research was conducted at the Integrative Biological Imaging Facility at Creighton University, Omaha, Nebraska. This facility, supported by the C.U. Medical School, was constructed with support from grants from the National Center for Research Resources (5P20RR016469) and the National Institutes for General Medical Science (NIGMS; 8P20GM103427), a component of the National Institutes of Health (NIH). This investigation is solely the responsibility of the authors and does not necessarily represent the official views of the NIGMS or NIH. The authors would also like to thank the Health Futures Foundation for their financial support.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2013/8
Y1 - 2013/8
N2 - Europium (Eu), dysprosium (Dy), samarium (Sm), and terbium (Tb) complexes were prepared using the neutral tridentate chelator 2,6-bis(1-benzyl-1,2,3-triazol-4-yl)pyridine and one equivalent of each lanthanide salt. The physicochemical, aerodynamic, and in vitro cellular properties of each lanthanide metal complex were studied to determine their viability as cell surface fluorescent probes. Each compound was characterized by electrospray ionization mass spectroscopy (ESI-MS), ultraperformance liquid chromatography (UPLC), differential scanning calorimetry (DSC), and thermogravimetic analysis (TGA). Upon excitation at 320 nm each complex displayed characteristic lanthanide-based fluorescence emission in the visible wavelength range with stokes shifts greater than 200 nm. Each complex was found to be chemically stable when exposed to pH range of 1-11 for 72 h and resistant to photobleaching. To simulate pulmonary administration of these fluorophores, the aerodynamic properties of the Eu and Tb complexes were determined using a next generation impactor (NGI). This measurement confirmed that the complexes retain their fluorescence emission properties after nebulization. Cellular cytotoxicity was determined on A-549 lung cancer cell line using methylthiazol tetrazolium (MTT) cytotoxicity assay at 24, 48, and 72 h postexposure to the complexes. The complexes showed a dose and time-dependent effect on the percent viability of the cells.
AB - Europium (Eu), dysprosium (Dy), samarium (Sm), and terbium (Tb) complexes were prepared using the neutral tridentate chelator 2,6-bis(1-benzyl-1,2,3-triazol-4-yl)pyridine and one equivalent of each lanthanide salt. The physicochemical, aerodynamic, and in vitro cellular properties of each lanthanide metal complex were studied to determine their viability as cell surface fluorescent probes. Each compound was characterized by electrospray ionization mass spectroscopy (ESI-MS), ultraperformance liquid chromatography (UPLC), differential scanning calorimetry (DSC), and thermogravimetic analysis (TGA). Upon excitation at 320 nm each complex displayed characteristic lanthanide-based fluorescence emission in the visible wavelength range with stokes shifts greater than 200 nm. Each complex was found to be chemically stable when exposed to pH range of 1-11 for 72 h and resistant to photobleaching. To simulate pulmonary administration of these fluorophores, the aerodynamic properties of the Eu and Tb complexes were determined using a next generation impactor (NGI). This measurement confirmed that the complexes retain their fluorescence emission properties after nebulization. Cellular cytotoxicity was determined on A-549 lung cancer cell line using methylthiazol tetrazolium (MTT) cytotoxicity assay at 24, 48, and 72 h postexposure to the complexes. The complexes showed a dose and time-dependent effect on the percent viability of the cells.
UR - http://www.scopus.com/inward/record.url?scp=84881013774&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84881013774&partnerID=8YFLogxK
U2 - 10.1002/jps.23616
DO - 10.1002/jps.23616
M3 - Article
C2 - 23761019
AN - SCOPUS:84881013774
VL - 102
SP - 2589
EP - 2598
JO - Journal of Pharmaceutical Sciences
JF - Journal of Pharmaceutical Sciences
SN - 0022-3549
IS - 8
ER -